/C O R R E C T I O N FROM SOURCE - Procyon Biopharma Inc./ Procyon Biopharma Announces Results of Their Canadian Phase II, Dose-Ranging Study For The Treatment of Hypertrophic Scarring - Fibrostat(R) multicentre study confirms safety and indicates

Announcing OEM Micro Solutions: Application-Based Integration and More (PR Newswire)
...Systems are developed for both embedded and stand-alone applications, and include all levels of system development, p...

Two New Reports Highlight Testing Innovations, Model Contractor Standards; ELC, AccountabilityWorks Documents Address Key Challenges (U.S. Newswire)
..."After a decade in which each state has largely tried to ’do it alone,’ the State Innovation Priorities r...

Justices Bar Death Penalty for Retarded Defendants (The New York Times)
...Surveying this rapidly changing landscape, Justice Stevens noted that the numbers alone did not tell the full story.....

Meridian Launches a New Product (Business Wire)
...Projected revenues for this new product in Korea alone is expected to be US$671,769 in 2002.......

La-Z-Boy Incorporated to Ring in 75th Anniversary at New York Stock Exchange (PR Newswire)
... dedicated exclusively to selling La-Z-Boy Incorporated products and brands, and includes 297 stand-alone La-......

Health Concerns Blossoming for Voters (Reuters)
..."It’s bigger than Medicare alone," said John Rother, policy director of the AARP, the influential retiree lobby...